Hepatitis C

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA Expands Indication, Adds Boxed Warning for HCV Drug

By

FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.

Low Rates of HCV Testing Seen in Baby Boomers

Low Rates of HCV Testing Seen in Baby Boomers

Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

By

The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.

French Study Points to Eradication of HIV-HCV Coinfection

French Study Points to Eradication of HIV-HCV Coinfection

By

Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

By

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

By

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

By

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

By

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

By

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

By

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

Multiple Updates for Atazanavir and Cobicistat HIV Combination Tx

By

Evotaz label has been updated to include data from Trial 114 including updates to the drug interactions and specific populations sections.

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.

ART Improves Liver Fibrosis in Majority of Patients With HIV

ART Improves Liver Fibrosis in Majority of Patients With HIV

By

Combination antiretroviral therapy is associated with an overall reduction in liver fibrosis in HIV-infected patients with and without hepatitis co-infections.

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Researchers found that 50.5% of the patients achieved sustained viral response, which correlated with reduced incidence of hepatocellular carcinoma and hepatic decompensation.

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

By

The 8-week regimen of LDV/SOF for HCV genotype 1 induced sustained virologic response at 12 weeks in nearly all patients treated.

HCV Antivirals Produce Durable Responses Despite Time to Suppression

HCV Antivirals Produce Durable Responses Despite Time to Suppression

By

Newer combinations of HCV genotype 1b antivirals showed sustained virologic response independent of time to viral suppression.

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Phase 2 multi-center study examined the efficacy and safety of ledipasvir-sofosbuvir in 100 adolescents with chronic HCV genotype 1 infection.

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

By

NDA submitted to the FDA by AbbVie for its investigational regimen of glecaprevir/pibrentasvir to treat all major genotypes of chronic HCV.

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes increased the risk of hepatocellular carcinoma development and all-cause mortality in patients infected with HCV.

WHO Prequalifies First HCV Rapid Diagnostic Test

WHO Prequalifies First HCV Rapid Diagnostic Test

By

The World Health Organization has just prequalified its first hepatitis C virus point-of-care diagnostic test.

FDA: Review Underway for Single Tablet HCV Regimen

FDA: Review Underway for Single Tablet HCV Regimen

By

The once-daily single tablet regimen of sofosbuvir/velpatasvir/voxilaprevir is intended for patients with direct-acting antiviral-experienced hepatitis C infections.

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Safety and efficacy was shown in kidney transplant recipients with hepatitis C virus genotype 1 or 4 infection.

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV treatment before liver transplant increased life expectancy if model for end-stage liver disease was ≤ 27.

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

By

Researchers evaluated the prevalence of late recurrent viremia following sofosbuvir-based treatment.

Possible Interaction Between HCV Treatment Identified

Possible Interaction Between HCV Treatment Identified

Probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) plus ribavirin with warfarin identified in a case report.

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

High prices have been a barrier to HCV treatment but WHO reports that prices in low- and certain middle-income countries are declining.

Sign Up for Free e-newsletters